Published in J Mol Biol on September 02, 2009
Small-angle scattering for structural biology--expanding the frontier while avoiding the pitfalls. Protein Sci (2010) 3.30
A molecular basis for the exquisite CD1d-restricted antigen specificity and functional responses of natural killer T cells. Immunity (2011) 2.11
The Vα14 invariant natural killer T cell TCR forces microbial glycolipids and CD1d into a conserved binding mode. J Exp Med (2010) 1.50
Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci U S A (2010) 1.37
Molecular basis of lipid antigen presentation by CD1d and recognition by natural killer T cells. Immunol Rev (2012) 0.99
Synthesis of immunostimulatory alpha-C-galactosylceramide glycolipids via Sonogashira coupling, asymmetric epoxidation, and trichloroacetimidate-mediated epoxide opening. Org Lett (2010) 0.95
Avidity of CD1d-ligand-receptor ternary complex contributes to T-helper 1 (Th1) polarization and anticancer efficacy. Proc Natl Acad Sci U S A (2011) 0.91
Stimulation of natural killer T cells by glycolipids. Molecules (2013) 0.91
Enhanced TCR footprint by a novel glycolipid increases NKT-dependent tumor protection. J Immunol (2013) 0.89
Human and mouse type I natural killer T cell antigen receptors exhibit different fine specificities for CD1d-antigen complex. J Biol Chem (2012) 0.88
Targeting the diverse immunological functions expressed by hepatic NKT cells. Expert Opin Ther Targets (2011) 0.86
Role for lysosomal phospholipase A2 in iNKT cell-mediated CD1d recognition. Proc Natl Acad Sci U S A (2013) 0.85
Amide analogues of CD1d agonists modulate iNKT-cell-mediated cytokine production. ACS Chem Biol (2012) 0.83
Divergent synthetic approach to 6''-modified α-GalCer analogues. Org Biomol Chem (2011) 0.83
Raising the roof: the preferential pharmacological stimulation of Th1 and th2 responses mediated by NKT cells. Med Res Rev (2012) 0.82
Design and Evaluation of ω-Hydroxy Fatty Acids Containing α-GalCer Analogues for CD1d-Mediated NKT Cell Activation. ACS Med Chem Lett (2014) 0.81
Structural Insights into High Density Lipoprotein: Old Models and New Facts. Front Pharmacol (2016) 0.77
An in silico approach for modelling T-helper polarizing iNKT cell agonists. PLoS One (2014) 0.77
The CD1 family: serving lipid antigens to T cells since the Mesozoic era. Immunogenetics (2016) 0.76
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr (1997) 137.43
Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr D Biol Crystallogr (2001) 15.88
The biology of NKT cells. Annu Rev Immunol (2007) 14.43
CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science (1997) 13.67
Fluorine in pharmaceuticals: looking beyond intuition. Science (2007) 8.98
Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol (2005) 7.08
CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature (2007) 5.31
Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest (2004) 5.16
Crystal structure of mouse CD1: An MHC-like fold with a large hydrophobic binding groove. Science (1997) 4.27
The crystal structure of human CD1d with and without alpha-galactosylceramide. Nat Immunol (2005) 3.53
Germline-encoded recognition of diverse glycolipids by natural killer T cells. Nat Immunol (2007) 3.19
Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. Nat Immunol (2005) 3.12
Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical. Immunity (1999) 2.86
Structure of myohemerythrin in the azidomet state at 1.7/1.3 A resolution. J Mol Biol (1987) 2.79
The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation. J Exp Med (2007) 2.37
CD1 antigen presentation: how it works. Nat Rev Immunol (2007) 2.27
Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. J Exp Med (2005) 2.18
Effects of lipid chain lengths in alpha-galactosylceramides on cytokine release by natural killer T cells. J Am Chem Soc (2004) 2.05
alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat Rev Immunol (2005) 2.02
Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation. Immunity (2009) 2.00
Structural basis of inhibitor selectivity in MAP kinases. Structure (1998) 1.89
Crystal structures of mouse CD1d-iGb3 complex and its cognate Valpha14 T cell receptor suggest a model for dual recognition of foreign and self glycolipids. J Mol Biol (2008) 1.72
Design of natural killer T cell activators: structure and function of a microbial glycosphingolipid bound to mouse CD1d. Proc Natl Acad Sci U S A (2006) 1.66
The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J Clin Invest (2004) 1.61
The T cell antigen receptor expressed by Valpha14i NKT cells has a unique mode of glycosphingolipid antigen recognition. Proc Natl Acad Sci U S A (2004) 1.61
A minimal binding footprint on CD1d-glycolipid is a basis for selection of the unique human NKT TCR. J Exp Med (2008) 1.60
Conversion of a T cell antagonist into an agonist by repairing a defect in the TCR/peptide/MHC interface: implications for TCR signaling. Immunity (2000) 1.48
Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity. J Am Chem Soc (2006) 1.47
Cutting edge: nonglycosidic CD1d lipid ligands activate human and murine invariant NKT cells. J Immunol (2008) 1.17
Immunotherapeutic potential for ceramide-based activators of iNKT cells. Trends Pharmacol Sci (2005) 1.16
E and Z alpha-C-galactosylceramides by Julia-Lythgoe-Kocienski chemistry: a test of the receptor-binding model for glycolipid immunostimulants. Chembiochem (2006) 1.04
Quantitative microarray analysis of intact glycolipid-CD1d interaction and correlation with cell-based cytokine production. J Am Chem Soc (2008) 1.01
Antibody recognition of a highly conserved influenza virus epitope. Science (2009) 11.26
Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature (2011) 11.07
Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science (2006) 10.04
HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48
The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J Virol (2002) 7.82
Structure of a V3-containing HIV-1 gp120 core. Science (2005) 7.69
How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol (2006) 7.57
Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci U S A (2004) 7.55
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science (2004) 6.70
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
Recognition of bacterial glycosphingolipids by natural killer T cells. Nature (2005) 6.38
Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J Mol Biol (2005) 6.17
Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science (2010) 6.10
Structural genomics of the Thermotoga maritima proteome implemented in a high-throughput structure determination pipeline. Proc Natl Acad Sci U S A (2002) 6.00
A highly conserved neutralizing epitope on group 2 influenza A viruses. Science (2011) 5.66
Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol (2003) 5.59
Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science (2013) 5.53
Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol (2006) 5.51
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science (2011) 5.44
A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. J Virol (2005) 4.71
Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science (2013) 4.61
Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J Exp Med (2007) 4.47
Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science (2011) 4.42
Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science (2007) 4.35
Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity (2005) 4.26
A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog (2013) 4.23
Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat Chem Biol (2006) 4.20
New world bats harbor diverse influenza A viruses. PLoS Pathog (2013) 4.10
Protein production and purification. Nat Methods (2008) 3.97
Crystal structure of human toll-like receptor 3 (TLR3) ectodomain. Science (2005) 3.72
Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nat Immunol (2005) 3.70
Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci U S A (2005) 3.57
Rational HIV immunogen design to target specific germline B cell receptors. Science (2013) 3.55
Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science (2012) 3.53
Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. Nat Immunol (2011) 3.48
Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature (2008) 3.47
Highly conserved protective epitopes on influenza B viruses. Science (2012) 3.47
Exploration of uncharted regions of the protein universe. PLoS Biol (2009) 3.41
Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure (2004) 3.31
A Blueprint for HIV Vaccine Discovery. Cell Host Microbe (2012) 3.27
Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A (2010) 3.24
A dynamic knockout reveals that conformational fluctuations influence the chemical step of enzyme catalysis. Science (2011) 3.19
Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. Nat Immunol (2005) 3.12
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol (2013) 3.11
Crystal structure of a bacterial cocaine esterase. Nat Struct Biol (2002) 3.06
Recent avian H5N1 viruses exhibit increased propensity for acquiring human receptor specificity. J Mol Biol (2008) 3.00
Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci U S A (2013) 2.96
Glycan microarray technologies: tools to survey host specificity of influenza viruses. Nat Rev Microbiol (2006) 2.83
Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol (2004) 2.80
HIV-1 and influenza antibodies: seeing antigens in new ways. Nat Immunol (2009) 2.80
CLEC5A is critical for dengue-virus-induced lethal disease. Nature (2008) 2.79
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells. Proc Natl Acad Sci U S A (2007) 2.78
Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci U S A (2010) 2.77
Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci U S A (2002) 2.71
Glycoproteomic probes for fluorescent imaging of fucosylated glycans in vivo. Proc Natl Acad Sci U S A (2006) 2.70
Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog (2013) 2.66
Structural characterization of the 1918 influenza virus H1N1 neuraminidase. J Virol (2008) 2.63
T cell activation by lipopeptide antigens. Science (2004) 2.59
Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci U S A (2005) 2.50
Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature (2012) 2.44
Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc Natl Acad Sci U S A (2011) 2.38
Three-dimensional structural view of the central metabolic network of Thermotoga maritima. Science (2009) 2.33
Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc Natl Acad Sci U S A (2009) 2.31
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A (2012) 2.27
XtalPred: a web server for prediction of protein crystallizability. Bioinformatics (2007) 2.26
The molecular interaction of CAR and JAML recruits the central cell signal transducer PI3K. Science (2010) 2.26
Crystal structure of CD1a in complex with a sulfatide self antigen at a resolution of 2.15 A. Nat Immunol (2003) 2.20
Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. J Exp Med (2005) 2.18
Sulfatases: structure, mechanism, biological activity, inhibition, and synthetic utility. Angew Chem Int Ed Engl (2004) 2.18
Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing. Nat Biotechnol (2012) 2.14
Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J Virol (2008) 2.14
Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells. Proc Natl Acad Sci U S A (2005) 2.13
Structural basis of steroid hormone perception by the receptor kinase BRI1. Nature (2011) 2.12
Structural basis of TLR5-flagellin recognition and signaling. Science (2012) 2.10
Contrasting IgG structures reveal extreme asymmetry and flexibility. J Mol Biol (2002) 2.10
Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc Natl Acad Sci U S A (2013) 2.10
Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc Natl Acad Sci U S A (2008) 2.09
Hepatitis C virus E2 envelope glycoprotein core structure. Science (2013) 2.06
Outcome of a workshop on applications of protein models in biomedical research. Structure (2009) 2.05
Hemagglutinin-neuraminidase balance confers respiratory-droplet transmissibility of the pandemic H1N1 influenza virus in ferrets. Proc Natl Acad Sci U S A (2011) 2.04
The junctional adhesion molecule JAML is a costimulatory receptor for epithelial gammadelta T cell activation. Science (2010) 2.02
The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol (2004) 2.02
The specificity of TCR/pMHC interaction. Curr Opin Immunol (2002) 1.99
The CD100 receptor interacts with its plexin B2 ligand to regulate epidermal γδ T cell function. Immunity (2012) 1.98
Synthesis of sugar arrays in microtiter plate. J Am Chem Soc (2002) 1.96
Antibody elbow angles are influenced by their light chain class. J Mol Biol (2006) 1.96
Natural Sphingomonas glycolipids vary greatly in their ability to activate natural killer T cells. Chem Biol (2008) 1.95